Skip to content
Open access

Expression of Human Endogenous Retroviruses in Peripheral Blood of Acute and Chronically HIV-Infected Subjects and Effect of Antiretroviral Therapy

Jul 2026 · International Journal of Molecular Sciences · Vol 27, pp. 6025 · 0 citations · 40 references
Medicine

TL;DR

Investigating HERV-K transcription in particular of Human MMTV-like (HML) group-2 and 6 in peripheral blood of people with HIV found that HERV-K transcripts may be detected during both acute and chronic phases of the infection, with HML-6 showing higher expression compared to HML-2, predominantly within myeloid cells.

Abstract

Human endogenous retroviruses (HERVs) originate from ancient retroviral integration into the primate germline. Although most are defective proviruses, the most recently endogenized groups, like the HERV-K family, retain intact ORFs encoding retroviral proteins. HERVs usually remain transcriptionally silent, yet this status is reversible. Multiple HIV-HERV interactions, mainly mediated by the HIV Tat protein, lead to HERV transcription and protein production. The present study investigates HERV-K transcription in particular of Human MMTV-like (HML) group-2 and 6 in peripheral blood of people with HIV (PWH). Using different experimental approaches—such as single-cell and plasma transcriptomics-, we found that HERV-K transcripts may be detected during both acute and chronic phases of the infection, with HML-6 showing higher expression compared to HML-2, predominantly within myeloid cells. Effective combined antiretroviral therapy (cART) was able to significantly reduce HML-6 transcription, regardless of whether the treatment was initiated in the acute or late chronic phases of HIV infection. Notably, chronic infections showed higher HML-6 transcript levels compared to acute infections in both naïve and successfully cART-treated subjects, potentially associated with persistent immune dysregulation observed in chronic HIV infection, although a direct causal role of HML-6 expression remains to be established.

Read PDF

Similar papers

Review Aug 2026

Quiet but not silent: assessing the impact of intact and defective HIV proviral DNA in the brain.

PURPOSE OF REVIEW People with HIV (PWH) require lifelong antiretroviral therapy (ART) to maintain viral suppression, yet integrated HIV DNA persists in long-lived cellular reservoirs in blood and tissues. Most integrated proviruses are defective, meaning they contain deletions, hypermutation, packaging-signal defects, splice defects, or other defects that prevent production of replication-competent viruses. However, these genomes are not necessarily biologically inert as many remain capable of transcription and, in some cases, translation of viral proteins. RECENT FINDINGS Recent evidence has demonstrated that the brain is a stable reservoir of both intact and defective HIV despite viral suppression with ART. Whilst intact replication capable proviruses are known to induce cell activation and pathology, recent studies suggest that defective proviruses with large internal deletions and hypermutation can remain transcriptionally, and in some cases, translationally active and have now been linked with persistent immune activation during ART. Therefore, transcriptionally active defective proviral DNA may be a contributor to underlying neuropathogenesis in ART-suppressed PWH. SUMMARY Defective HIV proviruses make up the majority of the proviral reservoir across blood and tissue compartments. Although they are replication-incompetent, many remain transcriptionally and translationally competent and may contribute to chronic inflammation, antigen persistence, and neuropathology in ART-suppressed PWH.

Emily K Chalmers, Janna Jamal Eddine, Liam Yucel et al. · 0 citations
Open access Aug 2026

Sensitive detection of rare HIV-infected cells in the human brain by single-nucleus RNA sequencing

HIV-1 enters the central nervous system early after infection and establishes a long-lived reservoir that persists despite antiretroviral therapy. Single-cell and single-nucleus RNA sequencing provide powerful approaches to study HIV infection in the human brain, yet standardized and sensitive methods for identifying rare HIV-infected cells in these datasets remain limited. Here, we present a scalable multi-reference framework for detecting HIV RNA–positive cells in human CNS single-nucleus RNA-seq data. The pipeline integrates a modified HIV reference genome, subject-specific variant-updated HIV references, and a comprehensive HIV strain collection to improve viral read recovery and specificity. We applied this framework to 250 post-mortem brain samples from the SCORCH (Single Cell Opioid Responses in the Context of HIV) consortium spanning 12 brain regions and 102 donors, including people with and without HIV (PWH and PWoH). After screening, 48 samples from 35 donors comprising 559,207 high-quality nuclei were analyzed in depth. We identified 1,939 HIV RNA–positive cells exclusively in samples from PWH. Using conservative thresholds, 908 high-confidence infected cells were retained for downstream analyses. HIV RNA-positive cells were rare overall and strongly enriched in cases with HIV encephalitis. Microglia constituted the predominant infected population (79% of HIV RNA-positive cells), with substantially smaller contributions from oligodendrocytes, astrocytes, and neurons. In non-encephalitic brains, detectable infection was largely restricted to microglia, whereas in encephalitic tissue HIV RNA–positive cells were distributed across multiple CNS (Central Nervous System) lineages. Viral RNA burden followed a long-tailed distribution, with microglia retaining higher HIV transcript counts than other cell types. Recovered HIV reads were concentrated in the U3 region of the 5′ LTR and in the env gene, implicating regulatory and entry-associated regions as focal points of viral diversity in the brain. Together, these data establish a harmonized framework for identifying rare HIV-infected cells in CNS single-cell datasets and provide large-scale quantitative evidence that microglia represent the dominant and most persistent HIV-infected population in the human brain. This work offers a reference strategy and resource for future NeuroHIV studies aimed at defining, monitoring, and ultimately targeting CNS viral reservoirs.

Yuan-Yuan Cai, Nicholas C. Jacobs, Dana Gabuzda et al. · 0 citations
Open access Aug 2026

Genomic landscape of HIV-1 proviruses in ART-treated immunological non-responders

Background Immunological non-responders (INRs) and immunological responders (IRs) exhibit distinct patterns of immune reconstitution despite suppressive antiretroviral therapy (ART); however, the genetic characteristics of the HIV-1 reservoir in these groups remain poorly understood. This study investigates the landscape of HIV-1 proviruses in INRs and IRs, and its potential association with immune reconstitution. Methods Peripheral blood mononuclear cells (PBMCs) from 10 ART-treated INRs and 10 IRs were analyzed using near-full-length HIV-1 DNA amplification and PacBio third-generation sequencing to characterize genetically intact and defective proviral genomes. Intact open reading frames (ORFs) were further inferred using the CFEIntact tool. Results Compared with IRs, INRs had a higher total proviral genome per 106 PBMCs, although the difference did not reach statistically significance. INRs also displayed a significantly higher level of intact proviral genomes per 106 PBMCs and a trend toward a higher proportion of intact sequences. Defective proviruses remained the predominant component of the reservoir in both groups and were broadly comparable in number and composition. In both cohorts, proviral defects were more frequently observed in the 3′ half of the genome. Discussion Our study reveals a distinct proviral landscape in ART-treated INRs, characterized by elevated levels of intact proviral genomes. These observations suggest that the intact component of the reservoir may represent a clinically relevant feature of incomplete immune reconstitution, and provide a rationale for further studies of reservoir-directed interventions in this population.

Shengquan Tang, Yue Wang, Yanqiu Lu et al. · 0 citations
Open access Aug 2026

Selection of effective LRAs using a newly designed in vitro HIV latency reactivation protocol: toward future application in HIV samples

A simple and reproducible assay to identify compounds capable of reactivating latent virus, a key step in cure strategies, is developed and validated and identified Tandutinib, a tyrosine kinase and mTOR inhibitor, as a novel LRA candidate with appreciable latency-reversing activity in the ACH2 model.

A. Neri, Arianna Rotili, Elena Morrocchi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.